October 27, 2015 (Shareholders Foundation) - An investigation on behalf of investors of Neos Therapeutics Inc (NASDAQ:NEOS) shares over potential securities laws violations by Neos Therapeutics and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Neos Therapeutics Inc (NASDAQ:NEOS) concerning whether a series of statements by Neos Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Shares of Neos Therapeutics Inc (NASDAQ:NEOS) reached as high as $27.09 per share in August 2015.

On October 19, 2015 Neos Therapeutics Inc announced that, on October 16, 2015, the Company received a notification from the U.S. Food and Drug Administration (FDA) stating that, as part of its ongoing review of the Companys New Drug Application (NDA) for Cotempla XR-ODT (Methylphenidate Extended Release Orally Disintegrating) 10 mg, 20mg, and 30 mg tablets, it has identified deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time.

Shares of Neos Therapeutics Inc (NASDAQ:NEOS) declined to as low as $11.53 per share on October 22, 2015.